Brind.

Bioinvent and MSD Combine Antibody with Anti-PD-1 Therapy for Ovarian Cancer

3 reports, 1 independent Updated Oct 1
No new developments lately Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bioinvent and MSD partnered to combine Bioinvent's antibody with MSD's anti-PD-1 therapy. An abstract presented at ESMO reported Phase 1/2a data for this combination in platinum-resistant recurrent ovarian cancer. The study showed an objective response rate of 24% and a preliminary median progression-free survival of 4.2 months.

From pr-inside.com

Why it matters

Some supportBrind's analysis of the reports

The combination therapy increases the clinical utility and market potential of KEYTRUDA® in PRROC. The partnership validates Bioinvent's BI-1808 program and opens a path to commercialization for Bioinvent.

From pr-inside.com

Who's involved

  • MSDProvides the anti-PD-1 therapy KEYTRUDA® in the combination treatment.
  • BioinventDeveloped the anti-TNFR2 antibody BI-1808, which is combined with MSD's therapy.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • MSDSpeculative

    MSD might see increased revenue from KEYTRUDA® due to the combination therapy's clinical utility in PRROC.

  • BioinventSpeculative

    Bioinvent could see increased investment and commercialization opportunities for its BI-1808 program following the partnership.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story